The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 414-421

  Cato III, Allen ^a,b   Cavanaugh, John ^a   Shi, Harry ^a   Hsu, Ann ^a   Leonard, John ^a   Granneman, Richard ^a  

^a ABBOTT LABORATORIES   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; PLACEBO; RIFABUTIN; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; LEUKOPENIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; REFERENCE VALUES; RIFABUTIN; RITONAVIR;

EID: 0031900568     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90036-4     Document Type: Article

References (27)

1. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-8.
2. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
3. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease: European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995;333:1528-33.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HTV-1 infection. Nature 1995;373:123-6.
5. Hsu A, Granneman R, Rynkiewicz K, Valdes J, Mayer K, Leonard J. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses [abstract]. Pharm Res 1994;11:S-400.
6. Lea AP, Faulds D. Ritonavir. Drugs 1996;52:541-6.
7. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31.
8. Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-25.
9. Strolin Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990;20:1113-9.
10. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989;33:1237-41.
11. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985;63:1205-11.
12. Li RC, Narang PK, Poggesi I, Strolin-Benedetti S. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos 1996;17:223-36.
13. Cocchiara G, Strolin Benedetti M, Vicario GP, Ballabio M, Gioia B, Vioglio S, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989;19:769-80.
14. 14C-rifabutin in animals and man. J Antimicrob Chemother 1990;26:813-22.
15. O'Brien RJ, Lyle MA, Snider DE. Rifabutin (ansamycin LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987;9:519-30.
16. Koudriakova T, Iatsimirskaia E, Tulebaev S, Spetie D, Utkin I, Mullet D, et al. In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J Pharmacol Exp Ther 1996;279:1300-9.
17. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
18. De Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253:387-94.
19. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B 1997;704:307-13.
20. Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res 1991;8:1434-40.
21. Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstract]. In: Abstracts of the XI International Conference on AIDS. XI International Conference on AIDS Society, Vancouver, British Columbia, Canada.1996. p. 18.
22. Griffith DE, Brown BA, Girard WM, Wallace RJ. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-8.
23. Rifabutin. Physician's Desk Reference. Montvale (NJ): Medical Economics Company; 1998. p. 2282-4.
24. Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
25. Ouellet D, Hsu A, Granneman, Carlson G, Guenther H, Mukherjee D, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin [abstract]. Clin Pharmacol Ther 1996;59:143.
26. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996;335:377-83.
27. Siegal FP, Eilbott D, Burger H, Gehan K, Davidson B, Kaell AT, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 1990;4:433-41.